• Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

  • Feb 5 2025
  • Length: 37 mins
  • Podcast

Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

  • Summary

  • From high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients.

    Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp
    📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4
    📖Paperback: https://amzn.to/4gAXrz4

    💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
    USE CODE "OTP10" to save 10%.

    SOCIALS:
    📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx
    🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1
    👾: https://discord.gg/ZHeUh7WV
    📺: https://youtube.com/@ManOnTheMounjaro?feature=shared
    ❌: https://x.com/manonthepen?s=21
    💻: https://www.onthepen.com

    Show more Show less

What listeners say about Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.